Vona Oncology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vona Oncology is a private, pre-revenue biotech founded in 2018, developing VDX-431, a novel small molecule drug targeting aggressive cancers like TNBC, ovarian cancer, and melanoma. The company has raised $3.3 million in non-dilutive funding, primarily from government grants, and is currently in the pre-clinical stage, working towards an IND submission. Its strategy is to demonstrate early clinical efficacy in TNBC and leverage compelling pre-clinical data showing tumor growth inhibition and synergy with chemotherapy. Vona's long-term vision is to evolve into a discovery and development company translating novel cancer biology insights into clinical treatments.

Oncology

Technology Platform

Novel targeted small molecule platform focused on a specific biological target in aggressive cancers, with demonstrated synergy potential with standard chemotherapy.

Opportunities

The high unmet medical need in triple-negative breast cancer presents a significant market opportunity for a first-in-class or best-in-class targeted therapy.

Demonstrated pre-clinical synergy with chemotherapy could enable rapid integration into standard treatment regimens and support combination therapy strategies.

Success in the lead TNBC indication could efficiently pave the way for expansion into other aggressive cancers like ovarian cancer and melanoma.

Risk Factors

The company faces high clinical development risk, as pre-clinical success does not guarantee safety or efficacy in human trials.

Financial risk is elevated due to limited capital ($3.3M), necessitating near-term dilutive fundraising to advance into clinical stages.

Competitive and execution risks are substantial, given the intense R&D focus on oncology by larger, better-resourced companies and the challenges of managing clinical trials as a small, early-stage entity.

Competitive Landscape

The TNBC therapeutic landscape is competitive and evolving, with several antibody-drug conjugates (e.g., Sacituzumab govitecan) now approved and numerous targeted therapies in clinical development from large pharma and biotech firms. Vona's VDX-431 will need to differentiate itself through a novel mechanism of action, superior efficacy, or a favorable safety/tolerability profile. Its small molecule approach could offer advantages in dosing convenience compared to biologics.

More companies in Small Molecule Drugs →More companies in United States →